Bye bye, booze!
Sober up with science
Study Purpose: To determine whether gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and abstinence from heavy drinking and reduces alcohol-related insomnia, dysphoria, and craving in a dose-dependent manner.
Design, Participants, and Setting: A 12-week, double-blind, placebo-controlled, randomized dose-ranging study of 150 men and women aged 18 years and older with current alcohol dependence conducted from 2004 to 2010 in a single-site outpatient clinical research facility adjacent to a general medical hospital.
Interventions: Oral gabapentin (doses of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual counseling.
Conclusions and Relevance: Gabapentin (particularly the 1800-mg dose) was effective in treating alcohol dependence and relapse-related symptoms of insomnia, dysphoria, and cravings and had a favorable safety profile. Increased implementation of pharmacologic treatment for alcohol dependence in primary care could be a significant benefit of gabapentin as a treatment option for alcohol dependence.
JAMA Intern Med.: Gabapentin treatment for alcohol dependence: a randomized clinical trial
Powered by BetterDocs
This site is still under development. Feel free to look around and don't hesitate to give us feedback, you'll find a form at the end of each page.
Nevertheless, we activate a few cookies, and these cookies could change due to the fact. that it's a development-site.
Bye bye booze needs cookies, too. However, we try only to activate as few as possible technically necessary cookies so that your visit to this site cannot be tracked as far as possible by third parties.
However, we do need a few - e.g. to display this legal notice or to care for that you do not have to log in again for each page or see this popup again for each page.
As soon as you click on an external link or video, however, cookies may be set by the operators of these sites, which we cannot influence. Learn more on our privacy page.